Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$362.6MCash on Hand
84.2mo Cash Runway
Follow GHRS by emailGet an email when GHRS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about GHRS, unsubscribe in one click. Privacy
📣 What GHRS Says Is Next
second half of 2027 · GH001: “We plan to advance GH001 in PPD into a pivotal program with one fixed dose per treatment visit via the ADS and are targeting initiation in the second half of 2027, subject to final regulatory alignment.”
Company press release, Nov 13, 2026 · SEC filing
Q1 2027 · “We expect to hold an End-of-Phase 2 meeting with the FDA in Q1 2027 to finalize the design and to initiate the pivotal program in TRD shortly thereafter, subject to final alignment.”
Company press release, Nov 13, 2026 · SEC filing
in 2026 · “We continue to engage with the FDA on the design of the pivotal program, which is intended to replicate the Phase 2b trial, including consideration of recent FDA guidance issued in July 2026, and we continue to target initiation of our pivotal program in 2026.”
Company press release, Aug 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Oct 9, 2026 ·
GH Research will present data from its GH001-TRD-201 and GH001-BD-202 clinical trials in three posters at the ECNP meeting in Munich on October 11, 2026. The company will also sponsor a satellite symposium on treatment-resistant depression on October 10. Form 6-K · SEC filing
Sep 11, 2026 ·
GH Research will hold one-on-one investor meetings during the Morgan Stanley 24th Annual Global Healthcare Conference, scheduled for September 14 to 16, 2026, in New York. Form 6-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
May 2026 · Phase 1 · Results Expected · Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects Registry primary completion date, not a results date
Oct 2024 · Phase 2 · Results Expected · A Trial of GH001 in Patients With Treatment-resistant Depression Registry primary completion date, not a results date
Nov 2023 · Phase 1 · Results Expected · Safety and Pharmacokinetics of GH002 in Healthy Volunteers Registry primary completion date, not a results date
Nov 2021 · Phase 1/2 · Results Expected · Clinical Study of GH001 in Depression Registry primary completion date, not a results date
Oct 2021 · Phase 1 · Results Expected · Pharmacokinetics of GH001 in Healthy Volunteers Registry primary completion date, not a results date
Oct 2019 · Phase 1 · Results Expected · Safety of GH001 in Healthy Volunteers Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
GHRS holds $362.6M in cash and short-term investments and burns about $12.9M/quarter from operations,
an estimated runway of 84.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:22 · Moderate
Cash runway 84 months
ATM program on file since May 2026 +15
Shelf registration (F-3, May 2026) +10
Share count +19% in a year +7
Raised after last reported balance sheet (Apr 2026) -10
Share count 62,029,395 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full GHRS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GHRS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.